Inari Medical Joins the World Thrombosis Day Campaign as Global Benefactor to Raise Awareness of Life-Threatening Blood Clots

CHAPEL HILL, NC, USA – The World Thrombosis Day (WTD) campaign today announced that Inari Medical has joined the campaign as a Global Benefactor in support of its yearly global awareness initiative to reduce death and disability caused by thrombosis, also known as blood clots. Observed on 13 October, WTD, led by the International Society on Thrombosis and Haemostasis (ISTH), mobilizes 3,000 partner organizations to hold more than 10,000 awareness events worldwide each year. Last year alone, the campaign reached an estimated 3.9 billion people in an effort to shine a spotlight on the burden of this condition. 

Inari is a leading commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari is focused on treating venous thromboembolism (VTE) and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. 
 
“Inari Medical is honored to be joining ISTH & World Thrombosis Day in our shared mission to combat venous thromboembolism through education and improved therapy. Venous blood clots remain a leading cause of in-hospital mortality, with over 10 million patients impacted each year globally1. While similar in scope to arterial thrombotic diseases such as heart attack and stroke, VTE lacks the same standardized approach to diagnosis, triage, and follow-up to ensure optimal patient care with the best tools available. With so many affected and such a need for education of both HCPs and patients alike, we thank WTD & ISTH for their diligent efforts to further the conversation and advance the field. We look forward to our newfound collaboration to better serve our patients,” said Bill Hoffman, Inari Medical’s Chief Executive Officer.

One in four deaths worldwide is related to thrombosis, highlighting the urgent need for awareness and patient empowerment to ask for a risk assessment 2, 3. With the tagline, Eyes Open to Thrombosis, the campaign encourages the general public, healthcare professionals, and key decision makers to know and take action on the risk factors, signs and symptoms of the condition.

“As we recognize World Thrombosis Day this October, we are delighted to welcome Inari Medical to the campaign as a Global Benefactor and true champion of awareness,” said Prof. Beverley Hunt, O.B.E., Chair of the ISTH WTD Steering Committee. “Inari Medical’s partnership is critical to our efforts in raising awareness of VTE and its prevention and treatment, which ultimately saves lives.” 

To learn more and support World Thrombosis Day, visit www.worldthrombosisday.org. 

About Inari Medical 
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

About WTD
Launched in 2014 and held annually on 13 October, WTD aims to increase public, healthcare professional and health care systems’ awareness of thrombosis and, ultimately, to reduce deaths and disabilities from thromboembolic disease through a greater awareness of its causes, risk factors, signs and symptoms, and evidence-based prevention and treatment. WTD’s mission supports the World Health Assembly’s global target of reducing premature deaths by non-communicable disease by 25 percent by 2025, as well as the WHO global action plan for the prevention and control of non-communicable diseases in the 2013-2020 timeframe. Visit www.worldthrombosisday.org for more information and to get involved.

About the ISTH
Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. ISTH is an international professional membership organization with more than 5,000 clinicians, researchers and educators working together to improve the lives of patients in more than 98 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees and World Thrombosis Day on 13 October. Visit ISTH online at www.isth.org.

References
1 Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaisier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modeling of observational studies. BMJ Qual Saf 2013; 22;809-15. Retrieved from: http://qualitysafety.bmj.com/content/22/10/809.full.pdf+html
2 Journal of Thrombosis and Haemostasis, “Thrombosis: A Major Contributor to the Global Disease Burden.” www.worldthrombosisday.org/issue/global-burden-vte/
3 World Health Organization (WHO), “65th World Health Assembly Closes with New Global Health Measures,” (2012). www.who.int/mediacentre/news/releases/2012/wha65_closes_20120526/en/